Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Preferred Stock Liabilities (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $131.0 million as the latest value for Q4 2025.

  • Quarterly Preferred Stock Liabilities fell 8.31% to $131.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.0 million through Dec 2025, down 8.31% year-over-year, with the annual reading at $131.0 million for FY2025, 8.31% down from the prior year.
  • Preferred Stock Liabilities for Q4 2025 was $131.0 million at Rhythm Pharmaceuticals, down from $146.9 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $146.9 million in Q3 2025, with the low at $131.0 million in Q4 2025.